Navigation Links
EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models

198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, produc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... has completed enrollment of the additional subjects, as ... this year, into the company,s Phase 2 study ... regulator (IDR) and is being evaluated as a ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... 8, 2011 Elsevier Business Intelligence , ... conferences, is hosting Windhover,s 21 st Pharmaceutical Strategic ... in New York, NY. PSA is the only ... a diverse mix of pharma,s top talent. It,s an opportunity ...
... Medical, a leading manufacturer of integrated medical imaging display and ... year, Carrot Medical achieved significant growth in sales and an ... of 2011 with record second quarter sales, Carrot surpassed its ... company is now well positioned for the third straight year ...
Cached Medicine Technology:Biopharma Leaders Discuss Pharma's Future at Pharmaceutical Strategic Alliances in New York 2Biopharma Leaders Discuss Pharma's Future at Pharmaceutical Strategic Alliances in New York 3Carrot Medical Positioned for Third Straight Year of Triple Digit Growth 2
(Date:8/31/2015)... ... August 31, 2015 , ... Wound Care ... the company’s second Introduction to Hyperbaric Medicine Course. The next UHMS approved 40-hour ... Queen Mary Hotel in Long Beach, CA. The meeting is open for registration ...
(Date:8/31/2015)... NY (PRWEB) , ... August 31, 2015 , ... ... Mesothelioma is a one-day event geared to patients and family members, medical ... by local and regional mesothelioma experts. The conference is a collaborative effort between ...
(Date:8/31/2015)... ... ... Patients who thought about getting a hair transplant but were not sure ... procedure beyond the information found on the Internet can attend the open house event ... be on hand to answer patients hair transplant questions at his next Open ...
(Date:8/31/2015)... Newton, North Carolina (PRWEB) , ... August 31, 2015 , ... ... Abernethy Laurels on Tuesday, September 1. , “Alive Inside” shadows a social ... nonprofit “MUSIC & MEMORY?.” , “It’s a documentary about bringing music to residents in ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden ... in 2008, the result of a merger of five of the busiest urology ... they could provide more cost-effective and higher quality care than they did individually. ...
Breaking Medicine News(10 mins):Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Garden State Urology! 2
... the most important determinants of an individual,s risk of ... history whether and at what ages close relatives ... for screening examinations such as colonoscopies and mammograms. ... Medical Association a multi-institutional research team reports that ...
... , TUESDAY, July 12 (HealthDay News) -- Among ... patients are more likely than whites to develop the potentially ... pressure ulcers, greatly increase a patient,s cost of care and ... be prevented through proper care, such as helping a patient ...
... rates are higher for men than women in the United ... Biomarkers & Prevention , a journal of the American Association ... investigator in the division of cancer epidemiology and genetics at ... and survival data from the SEER database for 36 cancers ...
... give failing hearts a boost were originally developed as ... as the technology has improved, these ventricular assist devices ... vice-president Dick Cheney, whose implant this month celebrates its ... problems. The power cord that protrudes through the patient,s ...
... The sexually transmitted disease trichomoniasis may be much more common ... are recommending routine screening for sexually active women aged 40 ... prevalent in young people, but our study results clearly show ... even more, older women are infected," said the study,s senior ...
... By Alan Mozes HealthDay Reporter , MONDAY, July ... a perfect time for hitting the beach. But a summer ... much, caution researchers who report that such institutions tend to ... deaths whenever they undergo the massive medical resident turnover that ...
Cached Medicine News:Health News:Changes in family history of cancer can impact screening recommendations 2Health News:Changes in family history of cancer can impact screening recommendations 3Health News:Bed Sores Afflict More Blacks in Nursing Homes Than Whites: Study 2Health News:Cancer mortality rates are higher in men than women 2Health News:Wireless power could cut cord for patients with implanted heart pumps 2Health News:Wireless power could cut cord for patients with implanted heart pumps 3Health News:Older Women at Greater Risk for Common STD, Study Suggests 2Health News:Deaths Up, Care Levels Down at Teaching Hospitals in July 2Health News:Deaths Up, Care Levels Down at Teaching Hospitals in July 3Health News:Deaths Up, Care Levels Down at Teaching Hospitals in July 4
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
... New REFRESH LIQUIGEL® Lubricant Eye Drops ... with the convenience of a liquid ... protection. Its extra-strength CMC formula provides ... comfort. And with the PURITE® preservative, ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
... solution is an anti-infective prescription ... may instruct you to use ... infection caused by bacteria. Bacterial ... the 2 types of eye ...
Medicine Products: